Differentiation Induction in Acute Myelogenous Leukemia
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Hypothesis: Differentiation induction therapy in acute myelogenous leukemia (AML) can be used
to achieve disease control and stabilize peripheral blood counts in patients with acute
myelogenous leukemia.
Adult patients (<18 years of age) who can be included: Elderly patients (>60 years of age)
with newly diagnosed AML who cannot achieve standard chemotherapy, patients with relapsed or
resistant AML. Patients with relapsed or resistant AML who cannot receive intensive
chemotherapy.
Treatment: Patients will be treated with all-trans retinoic acid (oral administration),
valproic acid (7 days intravenous administration and later oral administration)and
theophyllamine (7 days intravenous administration and later oral administration). Duration of
treatment at least 2 months or until disease progression. Maximal duration of treatment 2
years.
Followup: Clinical evaluation, peripheral blood samples, bone marrow samples.